• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears once-daily ADHD capsule from Corium

March 3, 2021 By Sean Whooley

CoriumCorium (NSDQ:CORI) announced today that it received FDA approval for its once-daily Azstarys oral capsule for treating ADHD symptoms.

Boston-based Corium touts its Azstarys (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) drug as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients aged six years and older, according to a news release.

Azstarys consists of 30% immediate-release d-MPH and 70% extended-release novel SDX, a prodrug of d-MPH. After it is absorbed through the gastrointestinal tract, SDX is converted into d-MPH and designed to gradually release the therapeutic throughout the day, delivering rapid symptom control along with treatment for an extended duration.

Corium says the aim of Aztarys is to address unmet needs in the market, including early onset of action and long duration of therapy combined into steady symptom control in just one capsule.

The drug was evaluated in a study of 150 children aged six to 12 years old, which observed significant improvements in children treated with Azstarys compared to those receiving a placebo, although adverse events did occur more frequently in the treatment group.

“The FDA approval of Azstarys means Corium is one step closer to bringing this innovative therapy to market and providing patients with ADHD and their clinicians a new option for rapid and extended symptom control via the dual action of d-MPH and the novel d-MPH prodrug SDX,” Corium president & CEO Perry J. Sternberg said in the release. “The team at Corium is energized to leverage their deep ADHD and commercialization expertise to launch and market Azstarys, which is an important milestone for Corium and its focus on [central nervous system] therapies.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pediatrics, Pharmaceuticals, Regulatory/Compliance Tagged With: Corium

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS